SUMMARY The effect of quadruple chemotherapy (mustine, vincristine, procarbazine, and prednisolone) on gonadal function was investigated in 15 males and 2 females treated for Hodgkin's disease during childhood. The 2 females have regular menstrual cycles with evidence of ovulation in one. Twelve of the males have shown normal progression of pubertal development since completing their treatment. Nine out of 10 late pubertal or adult subjects had small testes but only one developed gynaecomastia. All 4 prepubertal subjects had normal basal and peak gonadotrophin responses to luteinising hormone-releasing hormone. Nine of the 12 subjects studied during puberty or adulthood had either an increased basal serum follicle-stimulating hormone (FSH) level or an exaggerated FSH response to luteinising hormone-releasing hormone. Each of the 6 males who provided semen for analysis was azoospermic after an interval of between 2-4 and 8 (mean 5.3) years after completion of treatment. We conclude that severe testicular damage is common after treatment with mustine, vincristine, procarbazine, and prednisolone in childhood. The germinal epithelium is particularly vulnerable and the resultant azoospermia is likely to be irreversible. The Leydig cells are less susceptible to cytotoxic-induced damage. Pubertal development is normal and there is no indication for androgen replacement therapy.
Combination chemotherapy has greatly improved the prognosis for patients treated for Hodgkin's disease. This has resulted in the survival of an increasing number of young patients, cured of this cancer, but at risk from the long-term side effects of chemotherapy. Almost all men treated with at least 6 courses of MVPP (mustine, vinblastine, procarbazine, and prednisolone) or MOPP (mustine, vincristine, procarbazine, and prednisolone) for Hodgkin's disease are rendered permanently azoospermic.' 20 Gonadal function in women is less severely affected by MVPP chemotherapy. In patients studied by Chapman et al.2 there was a 62% incidence of amenorrhoea after completion of treatment. There has only been one study of chemotherapy-induced gonadal dysfunction in patients treated for Hodgkin's disease in childhood; in that study Sherins et 
Patients and methods
Fifteen males and 2 females, treated for Hodgkin's disease during childhood, were studied. All except one patient had previously received combination chemotherapy with MOPP. The normal control data for the hCG tests were provided by 9 prepubertal boys originally investigated for possible hormonal disorders and who later proved to be endocrinologically normal.
Results
Eight males had been prepubertal when they received their chemotherapy and in 5 of them puberty has proceeded normally or even been completed. The other 3 remain prepubertal at ages of 9*8, 10, and 11 -8 years. Seven boys were pubertal at the time of treatment, 4 of whom have completed pubertal maturation. Four of the 5 men (Cases 1, 6, 11, and 15) had small testes-less than 15 ml-and all 5 late pubertal males (Cases 3, 4, 5, 7, and 9) had small testes (mean 7 ml) in comparison with the degree of pubertal development. Only one (Case 3) developed gynaecomastia and this was slight.
The 2 females had been treated between ages 11 and 12 years. Menarche had already occurred in Case 16 at age 11 years. Her periods were regular even while receiving chemotherapy. Case 17 was aged 14 years when menarche subsequently occurred. Her menstrual cycle is regular and ovulatory, as indicated by a plasma progesterone level of >25 nmol/l (7-87 ng/ml) on the 21st day of the cycle.
Basal serum FSH and LH concentrations and the peak gonadotrophin responses to LH-RH in the 15 males are shown in Figs 1 and 2. Cases 4, 5, 9, and 14 were studied more than once. The results for the 5 men have been graphically compared with those of the late pubertal controls. The comparison is valid as there is no significant difference between the basal serum FSH levels and the peak FSH and LH responses to LH-RH in the late pubertal and young adult control groups. The basal serum LH level is significantly higher in the young adult group however, and the upper limit of our normal range for this age group is I 1 0 mU/ml rather than 8 0 mU/ml as in the late pubertal group. All 4 prepubertal subjects had normal basal and peak gonadotrophin responses to LH-RH. Four subjects were studied in early puberty. Case 12 Thyroid function tests were normal in 6 subjects.
In 11 there was biochemical evidence of compensated thyroid dysfunction, in that they had normal serum triiodothyronine (1 *2-3 nmol/1; 0*78-1-95 ng/ml) and thyroxine (50-150 nmol/l; 3.9-11.7
V.g/100 mil) levels with a slightly increased serum TSH level (range [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] mUll; normal <6 mUll).
All 11 had received neck irradiation. Some degree of breast development may be seen in at least half of normal boys at some time during puberty. In our study gynaecomastia affected only one, compared with 9 out of 13 pubertal boys with gynaecomastia reported by Sherins et al.3 Such a high incidence of moderate or severe gynaecomastia was a major clinical feature of that study. It is difficult to understand this disparity. It is possible that some of our older boys had already experienced a minor degree of breast development and that this had regressed before chemotherapy started. However none had had moderate or severe gynaecomastia. Eight of our 12 pubertal boys had received mantle field irradiation but the radiation dose reaching the breast bud is minimal with this radiation field as the breasts are covered by lead blocks designed to protect as much lung tissue as possible from radiation damage. Indeed the one individual (Case 3) who developed gynaecomastia had received mantle field irradiation. Gynaecomastia in 1 out of 12 pubertal boys is similar to the incidence we observed in adult men (7 out of 74) treated with MVPP for Hodgkin's disease. 20 Three of the 4 prepubertal subjects showed subnormal testosterone responses to hCG stimulation although in one (Case 14) the impaired testosterone response was transient. In addition a raised basal LH level or exaggerated peak LH response to LH-RH was found in 8 pubertal or adult subjects. The abnormalities in LH and testosterone concentrations suggest that Leydig cell damage has occurred. However, our 9 late pubertal or adult males (Table 2) have basal testosterone levels within the normal range and all show a significant testosterone response to hCG stimulation. Pubertal development has progressed normally in these nine. Two men are now married and have normal libido and sexual activity. Thus although evidence of a minor degree of Leydig cell dysfunction is common, frank Leydig cell failure is rare.
We conclude that severe testicular damage is common after MOPP therapy in childhood. The germinal epithelium is particularly vulnerable and the resultant azoospermia is likely to be irreversible. The Leydig cells are less susceptible to cytotoxicinduced damage. Pubertal development proceeds quite normally and there is no indication for androgen replacement therapy.
